<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366349</url>
  </required_header>
  <id_info>
    <org_study_id>209635</org_study_id>
    <nct_id>NCT04366349</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3772847 Administered Subcutaneously in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK3772847, an anti-interleukin (IL) 33-receptor monoclonal antibody, is a novel treatment&#xD;
      for asthma. The purpose of this study to evaluate the safety and tolerability, PK and PD of&#xD;
      single ascending doses of GSK3772847 administered subcutaneously (SC) to healthy&#xD;
      participants. This study will also establish the bioavailability of SC formulation and&#xD;
      evaluate the safety in particular injection site tolerability of route. Participants will&#xD;
      either receive a single dose of 70 milligram (mg) GSK3772847 or placebo in (Cohort 1) and 140&#xD;
      mg GSK3772847 or placebo in Cohorts 2, 3 (Japanese participants) and 4 (Chinese&#xD;
      participants). The site of injection will be upper arm; abdomen or thigh for cohorts 1 and 2&#xD;
      with cohorts 3 and 4 will receive injections in the upper arm only. Approximately, the total&#xD;
      duration of study will be up to 89 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Actual">December 21, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double blind study and participants and investigator will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other situations which involve medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From 0 to t (AUC[0-t]) of GSK3772847</measure>
    <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847. Pharmacokinetic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC[0-infinity]) of GSK3772847</measure>
    <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of GSK3772847</measure>
    <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of GSK3772847</measure>
    <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2) of GSK3772847</measure>
    <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
    <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Decrease in Ratio to Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration</measure>
    <time_frame>Baseline and up to Day 85/early withdrawal</time_frame>
    <description>Blood samples were collected to measure free soluble ST2 concentration. Maximal decrease from Baseline was the largest decrease calculated across all time points post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose). Pharmacodynamic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal Increase in Ratio to Baseline in Total Soluble ST2 Concentration</measure>
    <time_frame>Baseline and up to Day 85/early withdrawal</time_frame>
    <description>Blood samples were collected to measure total soluble ST2 concentration. Maximal increase from Baseline was the largest increase calculated across all timepoints post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Confirmed Positive Anti-GSK3772847 Antibodies</measure>
    <time_frame>Days 1, 15, 29, 57 and 85/early withdrawal</time_frame>
    <description>Serum samples were collected at indicated time points and analyzed for the presence of anti-GSK3772847 antibodies using a tiered approach including a screening assay, a confirmation assay and calculation of titer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio to Baseline in Plasma 4 Beta-hydroxy (4BetaOH) Cholesterol/Cholesterol</measure>
    <time_frame>Baseline, Days 5, 15, 29 and 85/early withdrawal</time_frame>
    <description>Blood samples were collected at indicated time points to measure 4BetaOH cholesterol/cholesterol. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline value was the latest pre-dose assessment (Day 1 Pre-dose).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Participants receiving melrilimab (GSK3772847) 70 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving melrilimab (GSK3772847) 140 milligram (mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>melrilimab (GSK3772847) 70 milligram (mg)</intervention_name>
    <description>melrilimab (GSK3772837) will be available at a dose strength of 70 milligram per milliliter (mg/mL) in a 3 milliliter (mL) glass vial.</description>
    <arm_group_label>Participants receiving melrilimab (GSK3772847) 70 milligram (mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>melrilimab (GSK3772847) 140 milligram (mg)</intervention_name>
    <description>Two doses of melrilimab (GSK3772837) 70 milligram per milliliter (mg/mL) will be administered to achieve a dose strength of 140 milligram per milliliter (mg/mL)</description>
    <arm_group_label>Participants receiving melrilimab (GSK3772847) 140 milligram (mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match melrilimab (GSK3772847) will be available in the form of solution for injection in a 3 milliliter (mL) glass vial.</description>
    <arm_group_label>Participants receiving Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants age in between 18 to 65 years, at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, and cardiac monitoring. A&#xD;
             participant with a clinical abnormality or laboratory parameters not specifically&#xD;
             listed in the exclusion criteria that is outside the reference range for the&#xD;
             population being studied may be included only if the investigator, in consultation&#xD;
             with the Medical Monitor (if required), agree and document that the finding is&#xD;
             unlikely to introduce additional risk factors and will not interfere with the study&#xD;
             procedures or results.&#xD;
&#xD;
          -  Japanese participants are eligible based on meeting all of the following criteria:&#xD;
             healthy male and female participants born in Japan; are descendants of four ethnic&#xD;
             Japanese grandparents and two ethnic Japanese parents; holding a Japanese passport or&#xD;
             identity papers; being able to speak Japanese; have lived outside Japan for less than&#xD;
             10 years at the time of screening.&#xD;
&#xD;
          -  Chinese Participants are eligible based on meeting all of the following: healthy male&#xD;
             and female participants born in mainland China; are descendants of four Chinese&#xD;
             grandparents and two Chinese parents; holding a Chinese passport or identity papers;&#xD;
             being able to speak Chinese; have lived outside China for less than 10 years at the&#xD;
             time of screening; Body weight 35-150 kilogram (kg) and body mass index (BMI) within&#xD;
             the range 18-32 kilogram per square meter (kg/m2) (inclusive).&#xD;
&#xD;
          -  Female participant: A female participant is eligible to participate if she is not&#xD;
             pregnant or breastfeeding, and at least one of the following conditions applies; is&#xD;
             not a woman of childbearing potential (WOCBP) or is a WOCBP and using an acceptable&#xD;
             contraceptive method during the intervention period (at a minimum until after the last&#xD;
             dose of study intervention); the investigator should evaluate the effectiveness of the&#xD;
             contraceptive method in relationship to the first dose of study intervention; a WOCBP&#xD;
             must have a negative highly sensitive pregnancy test ([urine] as required by local&#xD;
             regulations) within 24 hours before the first dose of study intervention; if a urine&#xD;
             test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy&#xD;
             test is required,. In such cases, the participant must be excluded from participation&#xD;
             if the serum pregnancy result is positive; additional requirements for pregnancy&#xD;
             testing during and after study intervention are located; The investigator is&#xD;
             responsible for review of medical history, menstrual history, and recent sexual&#xD;
             activity to decrease the risk for inclusion of a woman with an early undetected&#xD;
             pregnancy.&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and in this&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alanine transaminase (ALT) &gt;2 times of (x) upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin &gt;1.5xULN (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is&#xD;
             fractionated and direct bilirubin &lt;35 percent [%]).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Ongoing or recurrent infections.&#xD;
&#xD;
          -  QT interval corrected for heart rate by Fridericia's formula (QTcF) &gt;450 millisecond&#xD;
             (msec) or any of the following abnormal and clinically significant electrocardiogram&#xD;
             (ECG) findings; sinus bradycardia &lt;45 beats per minute (bpm); sinus tachycardia &gt;=110&#xD;
             bpm; multifocal atrial tachycardia (wandering atrial pacemaker with rate &gt;100 bpm);&#xD;
             evidence of Mobitz II second degree or third degree atrioventricular (AV) block;&#xD;
             pathological Q waves (defined as wide [&gt;0.04 seconds] and deep [&gt;0.4 millivolt (mV) (4&#xD;
             millimeter (mm) with 10mm/mV setting)] or &gt;25% of the height of the corresponding R&#xD;
             wave, providing the R wave was &gt;0.5 mV [5 mm with 10mm/mV setting], appearing in at&#xD;
             least two contiguous leads; Evidence of ventricular ectopic couplets, bigeminy,&#xD;
             trigeminy or multifocal premature ventricular complexes; For participants without&#xD;
             complete right bundle branch block: QT interval corrected for heart rate by&#xD;
             Fridericia's formula (QTc[F]) &gt;=450 msec or an ECG that is unsuitable for QT&#xD;
             measurements (e.g., poor defined termination of the T wave); for participants with&#xD;
             complete right bundle branch block: QTc(F) &gt;=480 msec or an ECG that is unsuitable for&#xD;
             QT measurements (e.g., poor defined termination of the T wave); ST-T wave&#xD;
             abnormalities (excluding non-specific ST-T wave abnormalities); Clinically significant&#xD;
             conduction abnormalities (e.g., Wolff-Parkinson-White syndrome or bifascicular block&#xD;
             defined as complete left bundle branch block or complete right bundle branch block&#xD;
             with concomitant left fascicular block); Clinically significant arrhythmias (e.g.,&#xD;
             atrial fibrillation with rapid ventricular response, ventricular tachycardia).&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including saint [St] John's Wort) within 7 days (or 14 days if the drug&#xD;
             is a potential enzyme inducer) or 5 half-lives (whichever is longer) before the first&#xD;
             dose of study medication and until study completion, unless in the opinion of the&#xD;
             investigator and GlaxoSmithKline (GSK) Medical Monitor the medication will not&#xD;
             interfere with the study procedures or compromise participant safety.&#xD;
&#xD;
          -  The participant has been in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Presence of Hepatitis B surface antigen (HBsAg) at screening or within 3 months prior&#xD;
             to first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C antibody test result at screening or within 3 months prior to&#xD;
             first dose of study intervention.&#xD;
&#xD;
          -  Positive Hepatitis C ribonucleic acid (RNA) test result at screening or within 3&#xD;
             months prior to first dose of study intervention.&#xD;
&#xD;
          -  A positive test for human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 milliliter (mL) within 3 months.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Any history of substance abuse or a positive test for drugs of abuse at screening or&#xD;
             admission.&#xD;
&#xD;
          -  Known, pre-existing parasitic infestations within 6 months prior to Screening.&#xD;
&#xD;
          -  Vaccinated with live or attenuated vaccines within 4 weeks prior to receiving&#xD;
             investigational product (IP) and up to 6 months after dose administration of&#xD;
             GSK3772847.&#xD;
&#xD;
          -  A positive highly sensitive pregnancy test (urine or serum as required by local&#xD;
             regulations) at screening.&#xD;
&#xD;
          -  Positive urinary cotinine test indicative of smoking history at screening or each&#xD;
             in-house admission to the clinical research unit or regular use of tobacco- or&#xD;
             nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6&#xD;
             months prior to screening.&#xD;
&#xD;
          -  Participants with allergy or intolerance to a monoclonal antibody or biologic or to&#xD;
             any components of the formulation used in this study.&#xD;
&#xD;
          -  A vulnerable participant. defined as individuals whose willingness to volunteer in a&#xD;
             clinical trial may be unduly influenced by the expectation, whether justified or not,&#xD;
             of benefits associated with participation, or of a retaliatory response from senior&#xD;
             members of a hierarchy in case of refusal to participate.&#xD;
&#xD;
          -  Participants who work for the Sponsor, contract research organization (CRO), or one of&#xD;
             the study centers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <results_first_submitted>October 7, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <keyword>GSK3772847</keyword>
  <keyword>Tolerability</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04366349/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT04366349/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants who met the eligibility criteria were assigned to one of the four cohorts and were randomly allocated within each cohort to receive a single dose of either GSK3772847 or placebo. All treatments were administered subcutaneously. The site of injection was randomized to the upper arm, abdomen, or thigh for cohorts 1 and 2. Injection was given in the upper arm only in cohorts 3 and 4.</recruitment_details>
      <pre_assignment_details>A total of 65 participants were enrolled in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohorts 1 and 2: Placebo SC</title>
          <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: GSK3772847 70 mg SC</title>
          <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: GSK3772847 140 mg SC</title>
          <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
        </group>
        <group group_id="P4">
          <title>Cohorts 3 and 4: Placebo SC</title>
          <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
          <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
          <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohorts 1 and 2: Placebo SC</title>
          <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: GSK3772847 70 mg SC</title>
          <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: GSK3772847 140 mg SC</title>
          <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
        </group>
        <group group_id="B4">
          <title>Cohorts 3 and 4: Placebo SC</title>
          <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
          <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
          <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18-64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65-84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=85 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White: White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian: Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian: East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian: Japanese Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian: South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other situations which involve medical or scientific judgment.</description>
        <time_frame>Up to Day 85</time_frame>
        <population>Safety Population consisted of all randomized participants who took at least 1 dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2: Placebo SC</title>
            <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 3 and 4: Placebo SC</title>
            <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and other situations which involve medical or scientific judgment.</description>
          <population>Safety Population consisted of all randomized participants who took at least 1 dose of study intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve From 0 to t (AUC[0-t]) of GSK3772847</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847. Pharmacokinetic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
        <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From 0 to t (AUC[0-t]) of GSK3772847</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847. Pharmacokinetic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4139.092" spread="34.1"/>
                    <measurement group_id="O2" value="10271.279" spread="25.2"/>
                    <measurement group_id="O3" value="13356.462" spread="29.7"/>
                    <measurement group_id="O4" value="11285.792" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC[0-infinity]) of GSK3772847</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
        <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve From Time Zero to Infinity (AUC[0-infinity]) of GSK3772847</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4336.865" spread="32.9"/>
                    <measurement group_id="O2" value="10575.235" spread="25.2"/>
                    <measurement group_id="O3" value="13936.982" spread="34.0"/>
                    <measurement group_id="O4" value="11576.445" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of GSK3772847</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
        <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of GSK3772847</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8276" spread="38.4"/>
                    <measurement group_id="O2" value="15.0569" spread="24.5"/>
                    <measurement group_id="O3" value="15.9309" spread="25.5"/>
                    <measurement group_id="O4" value="15.8324" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Cmax (Tmax) of GSK3772847</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
        <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Cmax (Tmax) of GSK3772847</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.000" lower_limit="48.00" upper_limit="382.42"/>
                    <measurement group_id="O2" value="130.358" lower_limit="71.95" upper_limit="311.80"/>
                    <measurement group_id="O3" value="146.175" lower_limit="144.93" upper_limit="312.63"/>
                    <measurement group_id="O4" value="204.925" lower_limit="72.00" upper_limit="381.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2) of GSK3772847</title>
        <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
        <time_frame>Day 1: Pre-dose, 2, 4, 8 hours post-dose; Days 2, 3, 4, 5, 6, 9, 15, 29, 43, 57, 71 and 85</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2) of GSK3772847</title>
          <description>Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3772847.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.275" spread="17.1"/>
                    <measurement group_id="O2" value="293.144" spread="27.6"/>
                    <measurement group_id="O3" value="342.622" spread="36.8"/>
                    <measurement group_id="O4" value="291.690" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Decrease in Ratio to Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration</title>
        <description>Blood samples were collected to measure free soluble ST2 concentration. Maximal decrease from Baseline was the largest decrease calculated across all time points post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose). Pharmacodynamic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
        <time_frame>Baseline and up to Day 85/early withdrawal</time_frame>
        <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2: Placebo SC</title>
            <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 3 and 4: Placebo SC</title>
            <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Decrease in Ratio to Baseline in Free Soluble Suppressor of Tumorigenicity 2 (ST2) Concentration</title>
          <description>Blood samples were collected to measure free soluble ST2 concentration. Maximal decrease from Baseline was the largest decrease calculated across all time points post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose). Pharmacodynamic Population consisted of all randomized participants who received at least one dose of study treatment, and for whom at least one pharmacokinetic sample was obtained, analyzed and measurable.</description>
          <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7573" lower_limit="0.6586" upper_limit="0.9660"/>
                    <measurement group_id="O2" value="0.0621" lower_limit="0.0512" upper_limit="0.0871"/>
                    <measurement group_id="O3" value="0.0417" lower_limit="0.0372" upper_limit="0.0511"/>
                    <measurement group_id="O4" value="0.8073" lower_limit="0.7150" upper_limit="0.9028"/>
                    <measurement group_id="O5" value="0.0453" lower_limit="0.0311" upper_limit="0.0638"/>
                    <measurement group_id="O6" value="0.0433" lower_limit="0.0399" upper_limit="0.0469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Increase in Ratio to Baseline in Total Soluble ST2 Concentration</title>
        <description>Blood samples were collected to measure total soluble ST2 concentration. Maximal increase from Baseline was the largest increase calculated across all timepoints post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose).</description>
        <time_frame>Baseline and up to Day 85/early withdrawal</time_frame>
        <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2: Placebo SC</title>
            <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 3 and 4: Placebo SC</title>
            <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Increase in Ratio to Baseline in Total Soluble ST2 Concentration</title>
          <description>Blood samples were collected to measure total soluble ST2 concentration. Maximal increase from Baseline was the largest increase calculated across all timepoints post dose. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline was the most recent recorded value before dosing on Day 1 (Pre-dose).</description>
          <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0573" lower_limit="-1.8417" upper_limit="10.8808"/>
                    <measurement group_id="O2" value="25.4604" lower_limit="22.1566" upper_limit="31.4077"/>
                    <measurement group_id="O3" value="40.6790" lower_limit="9.4889" upper_limit="112.2080"/>
                    <measurement group_id="O4" value="1.7203" lower_limit="1.1951" upper_limit="2.2921"/>
                    <measurement group_id="O5" value="39.1039" lower_limit="29.7883" upper_limit="50.6161"/>
                    <measurement group_id="O6" value="45.7791" lower_limit="35.8528" upper_limit="57.6231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Confirmed Positive Anti-GSK3772847 Antibodies</title>
        <description>Serum samples were collected at indicated time points and analyzed for the presence of anti-GSK3772847 antibodies using a tiered approach including a screening assay, a confirmation assay and calculation of titer.</description>
        <time_frame>Days 1, 15, 29, 57 and 85/early withdrawal</time_frame>
        <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2: Placebo SC</title>
            <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 3 and 4: Placebo SC</title>
            <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Confirmed Positive Anti-GSK3772847 Antibodies</title>
          <description>Serum samples were collected at indicated time points and analyzed for the presence of anti-GSK3772847 antibodies using a tiered approach including a screening assay, a confirmation assay and calculation of titer.</description>
          <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed (represented by n=X in the category titles).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: n=13,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: n=13,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: n=12,18,17,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57: n=12,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85/early withdrawal: n=12,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio to Baseline in Plasma 4 Beta-hydroxy (4BetaOH) Cholesterol/Cholesterol</title>
        <description>Blood samples were collected at indicated time points to measure 4BetaOH cholesterol/cholesterol. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline value was the latest pre-dose assessment (Day 1 Pre-dose).</description>
        <time_frame>Baseline, Days 5, 15, 29 and 85/early withdrawal</time_frame>
        <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Cohorts 1 and 2: Placebo SC</title>
            <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: GSK3772847 70 mg SC</title>
            <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2: GSK3772847 140 mg SC</title>
            <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
          </group>
          <group group_id="O4">
            <title>Cohorts 3 and 4: Placebo SC</title>
            <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
            <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
            <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio to Baseline in Plasma 4 Beta-hydroxy (4BetaOH) Cholesterol/Cholesterol</title>
          <description>Blood samples were collected at indicated time points to measure 4BetaOH cholesterol/cholesterol. Ratio to Baseline is defined as post-dose visit value divided by Baseline value. Baseline value was the latest pre-dose assessment (Day 1 Pre-dose).</description>
          <population>Pharmacodynamic Population. Only those participants with data available at indicated time points were analyzed (represented by n=X in the category titles).</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 5: n=13,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.117" lower_limit="0.979" upper_limit="1.274"/>
                    <measurement group_id="O2" value="0.998" lower_limit="0.945" upper_limit="1.053"/>
                    <measurement group_id="O3" value="1.092" lower_limit="0.976" upper_limit="1.221"/>
                    <measurement group_id="O4" value="1.062" lower_limit="0.580" upper_limit="1.944"/>
                    <measurement group_id="O5" value="1.051" lower_limit="0.951" upper_limit="1.163"/>
                    <measurement group_id="O6" value="1.192" lower_limit="0.941" upper_limit="1.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15: n=11,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.021" lower_limit="0.883" upper_limit="1.180"/>
                    <measurement group_id="O2" value="0.992" lower_limit="0.914" upper_limit="1.076"/>
                    <measurement group_id="O3" value="1.092" lower_limit="0.958" upper_limit="1.244"/>
                    <measurement group_id="O4" value="1.106" lower_limit="0.790" upper_limit="1.547"/>
                    <measurement group_id="O5" value="1.054" lower_limit="0.892" upper_limit="1.244"/>
                    <measurement group_id="O6" value="1.285" lower_limit="1.050" upper_limit="1.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29: n=12,18,17,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.119" lower_limit="0.942" upper_limit="1.329"/>
                    <measurement group_id="O2" value="0.980" lower_limit="0.912" upper_limit="1.052"/>
                    <measurement group_id="O3" value="1.200" lower_limit="1.033" upper_limit="1.394"/>
                    <measurement group_id="O4" value="1.143" lower_limit="0.854" upper_limit="1.528"/>
                    <measurement group_id="O5" value="1.041" lower_limit="0.893" upper_limit="1.215"/>
                    <measurement group_id="O6" value="1.488" lower_limit="1.162" upper_limit="1.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85/Early withdrawal: n=12,18,18,4,6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.923" lower_limit="0.821" upper_limit="1.037"/>
                    <measurement group_id="O2" value="1.032" lower_limit="0.941" upper_limit="1.132"/>
                    <measurement group_id="O3" value="0.901" lower_limit="0.798" upper_limit="1.017"/>
                    <measurement group_id="O4" value="0.930" lower_limit="0.701" upper_limit="1.235"/>
                    <measurement group_id="O5" value="0.826" lower_limit="0.727" upper_limit="0.939"/>
                    <measurement group_id="O6" value="0.946" lower_limit="0.723" upper_limit="1.237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, non-SAEs and SAEs were collected up to Day 85</time_frame>
      <desc>Safety Population consisted of all randomized participants who took at least 1 dose of study intervention.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohorts 1 and 2: Placebo SC</title>
          <description>Participants received a single dose of placebo subcutaneous (SC) injection in the upper arm, abdomen or thigh by a health care professional in Cohorts 1 and 2.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: GSK3772847 70 mg SC</title>
          <description>Participants received a single dose of GSK3772847 70 milligram (mg) SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 1.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: GSK3772847 140 mg SC</title>
          <description>Participants received a single dose of GSK3772847 140 mg SC injection in the upper arm, abdomen or thigh by a health care professional in Cohort 2.</description>
        </group>
        <group group_id="E4">
          <title>Cohorts 3 and 4: Placebo SC</title>
          <description>Japanese and Chinese participants received a single dose of placebo SC injection in the upper arm by a health care professional in Cohorts 3 and 4.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3: GSK3772847 140 mg SC in Japanese Participants</title>
          <description>Japanese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 3.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 4: GSK3772847 140 mg SC in Chinese Participants</title>
          <description>Chinese participants received a single dose of GSK3772847 140 mg SC injection in the upper arm by a health care professional in Cohort 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 23.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

